FDA delays PDUFA date for GSK's albiglutide

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA extended the PDUFA date by three months for a BLA for albiglutide ( GSK716155) to treat Type II diabetes. The new date is April 15, 2014; it was Jan. 1...